Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 34-40

  Jenkins, Peter ^a   Freeman, S ^b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Myeloid growth factors; Neutropenia; Risk models

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD EXAMINATION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEBRILE NEUTROPENIA; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; LABORATORY TEST; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

EID: 58949086798     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn560     Document Type: Article

References (20)

1. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995; 332: 901-906.
2. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211.
3. Group FAS. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 599-601.
4. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000; 36: S11-S14.
5. Link BK, Budd GT, Scott S et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care. Cancer 2001; 92: 1354-1367.
6. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003; 21: 4524-4531.
7. Silber JH, Fridman M, DiPaola RS et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998; 16: 2392-2400.
8. Rivera E, Haim Erder M, Fridman M et al. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: A validation study. Breast Cancer Res 2003; 5: R114-R120.
9. Savvides P, Terrin N, Erban J et al. Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: A potential decision aid for the use of myeloid growth factors. Support Care Cancer 2003; 11: 313-320.
10. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007; 43: 544-548.
11. Mouridsen H, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999; 19: 68a (Abstr 254).
12. Longo DL, Duffey PL, DeVita VT Jr et al. The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 1991; 9: 2042-2051.
13. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
14. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
15. Botnick LE, Hannon EC, Hellman S. A long lasting proliferative defect in the hematopoietic stem cell compartment following cytotoxic agents. Int J Radiat Oncol Biol Phys 1979; 5: 1621-1625.
16. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
17. Rivera E, Erder MH, Moore TD et al. Targeted filgrastim support in patients with early-stage breast carcinoma: Toward the implementation of a risk model. Cancer 2003; 98: 222-228.
18. Nabholtz JM, Cantin J, Chang J et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: Results of the BCIRG 004 trial. Clin Breast Cancer 2002; 3: 268-275.
19. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005; 201: 1771-1780.
20. Bonneterre J, Roche H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005; 23: 2686-2693.